Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 million people in 98 countries around the world. There are already 12 million infected people worldwide and two million new cases occur annually. Leishmaniasis has three main clinical presentations: cutaneous (CL), mucosal (ML), and visceral (VL). It is considered an opportunistic, infectious disease and the HIV-leishmaniasis correlation is well known. Antimonial compounds are used as first-line treatment drugs, but their toxicity, which can be extremely high, leads to a number of undesirable side effects and resultant failure of the patients to adhere to treatment. There is also a reported increase in Leishmania sp. resistance to these drugs. N...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Despite past 60 years of extensive research in antileishmanial drug development, the successful ther...
Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 mil...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
Abstract INTRODUCTION: Leishmaniasis is a global public health concern. Currently available treatm...
Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most c...
Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most c...
Leishmaniasis corresponds to a group of neglected tropical diseases caused by flagellated protozoa b...
Leishmaniasis is a major public health problem due to the high morbidity and mortality that it has w...
Leishmaniasis is a major public health problem due to the high morbidity and mortality that it has w...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Despite past 60 years of extensive research in antileishmanial drug development, the successful ther...
Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 mil...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
Abstract INTRODUCTION: Leishmaniasis is a global public health concern. Currently available treatm...
Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most c...
Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most c...
Leishmaniasis corresponds to a group of neglected tropical diseases caused by flagellated protozoa b...
Leishmaniasis is a major public health problem due to the high morbidity and mortality that it has w...
Leishmaniasis is a major public health problem due to the high morbidity and mortality that it has w...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Nanomedicine strategies were first adapted and successfully translated to clinical application for d...
Despite past 60 years of extensive research in antileishmanial drug development, the successful ther...